Biologics and biosimilars litigation update

    • - BST

Please join us for the second in our series of 2020 webinars on decisions in the United States and Europe impacting biologics and biosimilars.

Many of the top-selling drugs worldwide are biologics and several companies are seeking to produce biosimilars to compete in these lucrative markets. However, companies continue to face a great deal of uncertainty due to unresolved legal questions involving the governing statutes and patent rights.

Session 2 of this series will focus on recent key decisions, including:

  • Recent Federal Circuit decisions involving biologics and biosimilars.
  • Updates in the United States “patent thicket” antitrust litigation.
  • Recent developments in Europe including Kymab v Regeneron Supreme Court judgment in the UK.

Register here

Register for this event

Go to the event's page

Related events

3 September

09:00 - 10:00


Private equity - briefings on key legal terms


8 September

16:30 - 17:30


Protecting children's privacy online – GDPR and the ICO's Age Appropriate Design Code